Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 2c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.82), $0.02 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $19.2 million versus the consensus estimate of $14.8 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge
• Apple’s big price hike seen as "an unprecedented push to protect margins"